Related Experiment Video
Updated: Jun 3, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
Missing data issues at the FDA Center for Biologics Evaluation and Research
1Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Maryland, USA. John.Scott@fda.hhs.gov
Abstract:
Missing data in clinical trials pose a tremendous problem in the regulatory setting. The U.S. Food and Drug Administration relies on statistically rigorous evidence of safety and efficacy as a precondition for granting marketing approval for drugs, biologics, and many devices. The presence of missing data can compromise the integrity of any statistical analysis, further complicating a regulatory decision-making process with significant public health, legal, and financial implications. We review the unique missing data challenges faced by the Center for Biologics Evaluation and Research and discuss limitations in our current approach to these issues and potential directions for improvement.
More Related Videos
Related Concept Videos
Bioequivalence studies: Biowaivers
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
FDA Approved Drugs: Changes to Approved Drugs
Bioavailability Study Design: Healthy Subjects Versus Patients

